Pacira BioSciences Inc’s recently made public that its Senior Vice President, Finance RIKER LAUREN unloaded Company’s shares for reported $0.15 million on Jun 04 ’25. In the deal valued at $26.21 per share,5,578 shares were sold. As a result of this transaction, RIKER LAUREN now holds 59,564 shares worth roughly $1.45 million.
Then, WILLIAMS KRISTEN sold 14,376 shares, generating $377,226 in total proceeds. Upon selling the shares at $26.24, the Chief Administrative Officer now owns 161,574 shares.
Before that, RIKER LAUREN bought 5,579 shares. Pacira BioSciences Inc shares valued at $146,209 were divested by the Officer at a price of $26.21 per share.
Truist upgraded its Pacira BioSciences Inc [PCRX] rating to a Hold from a a Sell in a research note published on January 30, 2025; the price target was increased to $25 from $8. A number of analysts have revised their coverage, including Truist’s analysts, who decreased its forecast for the stock in mid August from “a Buy” to “a Sell”. RBC Capital Mkts also remained covering PCRX and has decreased its forecast on August 12, 2024 with a “Sector perform” recommendation from previously “an Outperform” rating. Raymond James revised its rating on August 12, 2024. It rated PCRX as “a Mkt perform” which previously was an “an Outperform”.
Price Performance Review of PCRX
On Tuesday, Pacira BioSciences Inc [NASDAQ:PCRX] saw its stock jump 0.21% to $24.39. Over the last five days, the stock has lost -1.93%. Pacira BioSciences Inc shares have risen nearly 29.46% since the year began. Nevertheless, the stocks have fallen -14.03% over the past one year. While a 52-week high of $29.61 was reached on 04/08/25, a 52-week low of $11.16 was recorded on 01/06/25.
Levels Of Support And Resistance For PCRX Stock
The 24-hour chart illustrates a support level at 23.98, which if violated will result in even more drops to 23.57. On the upside, there is a resistance level at 24.85. A further resistance level may holdings at 25.31.
